Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY

EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025

Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr

Total income for the period stood at Rs. 7101.28 crore

ALBIS unveils next-gen healthcare materials at COMPAMED 2025

ALBIS will present a selection of advanced materials from its broad healthcare portfolio

Caplin Point Laboratories’ subsidiary acquires land in Mexico

The investment in land is Rs. 19.85 crore

Lupin achieves S&P Global ESG score of 91

This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth

Novartis opens radioligand therapy facility in Carlsbad, US

Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio

Pfizer completes up to $10 billion acquisition of Metsera

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg

Dexlansoprazole delayed-release capsules are a proton pump inhibitor

Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

Daiichi Sankyo launches first-in-human trial of innovative cancer therapy

The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events